Refractory anaplastic astrocytoma responsive to PCV in combination with bevacizumab

We present a patient with anaplastic astrocytoma who had recurrent disease after treatment with surgery, radiation, procarbazine, lomustine (CCNU) and vincristine (PCV) over one year followed by poor response to second line treatment with temozolomide, irinotecan with bevacizumab, Novocure TTF thera...

Full description

Saved in:
Bibliographic Details
Published inCase reports in clinical pathology Vol. 2; no. 3; p. 17
Main Authors Swaminathan, Arun, Lightner, Donita D, Pittman, Thomas, Horbinski, Craig, Villano, John Lee
Format Journal Article
LanguageEnglish
Published United States 01.09.2015
Subjects
Brain tumor
Recurrent tumor
Tumor treatment
Anaplastic astrocytoma
Online AccessGet more information

Cover

More Information
Summary:We present a patient with anaplastic astrocytoma who had recurrent disease after treatment with surgery, radiation, procarbazine, lomustine (CCNU) and vincristine (PCV) over one year followed by poor response to second line treatment with temozolomide, irinotecan with bevacizumab, Novocure TTF therapy successively over a four year period after her initial treatment who then responded to PCV in combination with bevacizumab as third line therapy. This is the first report demonstrating benefit of concurrent PCV and bevacizumab treatment in a highly treatment refractory tumor.
ISSN:2331-2726
DOI:10.5430/crcp.v2n3p17